Monday, June 05, 2023 11:37:43 AM
https://www.businesswire.com/news/home/20230517005389/en/
VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced that Dr. Jennifer Bath, the company's Chief Executive Officer and President, will present at the Jefferies Healthcare Conference on Friday June 9, 2023, at 11:00 a.m. Eastern time.
The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx. The replay of the webcast will be available for 90 days.
Recent IPA News
- InterSystems et BioStrand, filiale d’IPA, collaborent au lancement de l’intégration innovante de la recherche vectorielle et de LENSai dans les applications de soins de santé pilotées par l’IA • Business Wire • 03/28/2024 06:35:00 PM
- InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications • Business Wire • 03/28/2024 11:02:00 AM
- IPA acquiert l'instrument Carterra LSA® pour améliorer la découverte d'anticorps et renforcer ses développements en matière d'IA • Business Wire • 03/20/2024 05:52:00 PM
- IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments • Business Wire • 03/20/2024 11:02:00 AM
- IPA présente ses résultats financiers et les récents points forts de son activité pour le troisième trimestre de l’exercice 2024* • Business Wire • 03/14/2024 11:39:00 PM
- IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* • Business Wire • 03/14/2024 12:05:00 PM
- BioStrand, filiale d'IPA, annonce une avancée majeure dans les sciences du vivant avec son Advanced Foundation AI Model utilisant l'empilement LLM et la technologie HYFT • Business Wire • 03/07/2024 08:24:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 04:19:01 PM
- IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology • Business Wire • 03/07/2024 12:02:00 PM
- L'IPA publiera ses résultats financiers et les faits marquants de sa récente activité pour le troisième trimestre de l'exercice 2024, le 14 mars 2024 • Business Wire • 03/04/2024 09:50:00 PM
- IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024 • Business Wire • 03/04/2024 01:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/23/2024 10:29:18 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/23/2024 10:26:04 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 02/15/2024 08:12:47 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/10/2024 06:53:08 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/10/2024 06:33:21 PM
- IPA présente ses résultats financiers et les récents points forts de son activité pour le deuxième trimestre de l’exercice 2024* • Business Wire • 12/14/2023 08:08:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 01:48:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 01:38:15 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 01:03:16 PM
- IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024* • Business Wire • 12/14/2023 01:01:00 PM
- IPA annonce la clôture d'une offre publique d'actions ordinaires pour un montant de 1 265 million de dollars • Business Wire • 12/09/2023 02:57:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/08/2023 10:11:10 PM
- IPA Announces Closing of $1.265 Million Public Offering of Common Shares • Business Wire • 12/08/2023 10:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/07/2023 09:53:47 PM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM